Levomilnacipran Extended-Release Capsules bulk supplier for pharma manufacturers

Levomilnacipran Extended-Release Capsules 20 mg, 40 mg, 80 mg, 120 mg Suppliers & Bulk Manufacturers

Available Forms: Extended-Release Capsules

Available Strengths: 20 mg, 40 mg, 80 mg, 120 mg

Reference Brands: Fetzima®(US)

Category: Psychiatry / Mental Health

Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases levels of these neurotransmitters in the brain to improve mood and energy. It is used for the treatment of major depressive disorder (MDD) in adults. The extended-release formulation allows for once-daily dosing and provides consistent therapeutic levels throughout the day.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Levomilnacipran extended-release (ER) capsules are FDA-approved in the United States for the treatment of major depressive disorder (MDD) in adults. As a serotonin-norepinephrine reuptake inhibitor (SNRI), the ER formulation provides consistent plasma levels and once-daily dosing. U.S. regulations mandate boxed warnings for increased suicidal thoughts in young adults, GMP-compliant manufacturing, bioequivalence studies for generics, and post-marketing pharmacovigilance. In the European Union, levomilnacipran is not widely marketed, but companies may pursue national or decentralized procedures for approval. EU requirements include a comprehensive Risk Management Plan (RMP), clinical safety and efficacy data, and robust pharmacovigilance measures. For dossier-ready sourcing, visit Pharmatradz.com.

Levomilnacipran Extended-Release Capsules — third party manufacturing & bulk supply

Levomilnacipran Extended-Release Capsules 20 mg, 40 mg, 80 mg, 120 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Levomilnacipran Extended-Release Capsules is supplied as Extended-Release Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Levomilnacipran Extended-Release Capsules listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Levomilnacipran Extended-Release Capsule... →

Back to Listing

Frequently Asked Questions

Levomilnacipran is used to treat major depressive disorder (MDD) in adults. It helps improve mood, increase energy, and relieve other symptoms of depression such as loss of interest, fatigue, and difficulty concentrating.

Levomilnacipran is a synthetic pharmaceutical compound that acts as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by increasing the levels of serotonin and norepinephrine in the brain to restore neurotransmitter balance and alleviate depressive symptoms.

Levomilnacipran is marketed under the brand name Fetzima in the United States and other approved markets.

Levomilnacipran (Fetzima) is manufactured and marketed by Allergan / Forest Laboratories and distributed in multiple countries through authorized partners.

The generic name is Levomilnacipran.

The most recognized brand name is Fetzima.

Levomilnacipran is manufactured in regulated pharmaceutical facilities that comply with international quality and safety standards, including sites in the United States and other approved markets.